scholarly journals Liquid Biopsy in Patients with Thyroid Carcinoma

Liquid Biopsy ◽  
2019 ◽  
Author(s):  
Ilze Fridrihsone ◽  
Arnis Abolins ◽  
Andrejs Vanags ◽  
Dzeina Mezale ◽  
Guntis Bahs
Keyword(s):  
Thyroid Carcinoma ◽  
Liquid Biopsy

scholarly journals Extracellular Vesicles from Thyroid Carcinoma: The New Frontier of Liquid Biopsy

2019 ◽  
Vol 20 (5) ◽  
pp. 1114 ◽  
Author(s):  
Germana Rappa ◽  
Caterina Puglisi ◽  
Mark Santos ◽  
Stefano Forte ◽  
Lorenzo Memeo ◽  
...  
Keyword(s):  
Thyroid Carcinoma ◽  
Extracellular Vesicles ◽  
Liquid Biopsy ◽  
Thyroid Nodules ◽  
Endocrine System ◽  
Diagnostic Procedures ◽  
Lymph Node Involvement ◽  
Phospholipid Bilayer ◽  
Invasive Approach ◽  
Non Invasive

The diagnostic approach to thyroid cancer is one of the most challenging issues in oncology of the endocrine system because of its high incidence (3.8% of all new cancer cases in the US) and the difficulty to distinguish benign from malignant non-functional thyroid nodules and establish the cervical lymph node involvement during staging. Routine diagnosis of thyroid nodules usually relies on a fine-needle aspirate biopsy, which is invasive and often inaccurate. Therefore, there is an urgent need to identify novel, accurate, and non-invasive diagnostic procedures. Liquid biopsy, as a non-invasive approach for the detection of diagnostic biomarkers for early tumor diagnosis, prognosis, and disease monitoring, may be of particular benefit in this context. Extracellular vesicles (EVs) are a consistent source of tumor-derived RNA due to their prevalence in circulating bodily fluids, the well-established isolation protocols, and the fact that RNA in phospholipid bilayer-enclosed vesicles is protected from blood-borne RNases. Recent results in other types of cancer, including our recent study on plasma EVs from glioblastoma patients suggest that information derived from analysis of EVs from peripheral blood plasma can be integrated in the routine diagnostic tumor approach. In this review, we will examine the diagnostic and prognostic potential of liquid biopsy to detect tumor-derived nucleic acids in circulating EVs from patients with thyroid carcinoma.

Potential of Liquid Biopsy in Papillary Thyroid Carcinoma in Context of miRNA, BRAF and p53 Mutation

2018 ◽  
Vol 19 (14) ◽  
pp. 1721-1729 ◽  
Author(s):  
Ewelina Perdas ◽  
Robert Stawski ◽  
Dariusz Nowak ◽  
Maria Zubrzycka
Keyword(s):  
Papillary Thyroid Carcinoma ◽  
Thyroid Carcinoma ◽  
Liquid Biopsy ◽  
P53 Mutation ◽  
Papillary Thyroid

scholarly journals Ultrasensitive Detection of BRAF Mutations in Circulating Tumor DNA of Patients With Metastatic Thyroid Cancer

2021 ◽  
Vol 5 (Supplement_1) ◽  
pp. A872-A873
Author(s):  
Mohamed A Gouda ◽  
Emily Ong ◽  
Helen J Huang ◽  
Laron McPhaul ◽  
Steve Yoon ◽  
...  
Keyword(s):  
Thyroid Cancer ◽  
Thyroid Carcinoma ◽  
Liquid Biopsy ◽  
Braf V600e ◽  
Molecular Testing ◽  
Ultrasensitive Detection ◽  
Tumor Type ◽  
Proof Of Concept ◽  
Braf Mutations ◽  
Mutant Braf

Abstract Background: Liquid biopsy is a promising technology that can offer various advantages for molecular testing over tissue-based approaches. Most studies trying to address the utility of liquid biopsy in thyroid cancer have failed so far to achieve satisfactory rates of detection of relevant mutations. In this study, we examined a newly developed approach for ultrasensitive detection of oncogenic mutations in thyroid cancer using BRAF mutation as a proof-of-concept. In an exploratory analysis, we also correlated our findings with clinical outcomes and with levels of standard of care biomarkers. Methods: We included a group of patients with metastatic thyroid carcinoma. Cell free DNA (cfDNA) was isolated from an average of 2 ml of plasma and from matched formaldehyde fixed paraffin tissue blocks (FFPB) that were obtained from prior surgery. Extracted DNA was subject to preamplification of mutant copies using Q5 High-Fidelity PCR kit. Digital droplet PCR was performed on pre-amplified purified DNA where BRAF mutated allele frequencies (AF) were measured using BioRad ddPCR Qx200. Results: Thirty-three patients were included in our study with a median age at diagnosis of 62. Our method achieved a sensitivity of detection of 47.6% and a specificity of 80%. Mutant BRAF V600E was detected in cfDNA of 54.5% of patients (n=18) compared to 80.8% in isolated DNA from matched FFPB. Median overall survival (OS) was shorter in patients with wild type (WT) BRAF in both ctDNA and tissue (127m vs 218m, p=0.015; 116m vs 223m, p=0.004). Thyroglobulin (Tg) levels did not correlate with BRAF mutations either quantitatively or qualitatively. In the papillary thyroid carcinoma-classic variant cohort (n=20), however, patients with cfDNA mutant BRAF were more likely to have elevated Tg (90.9% versus 44.4% respectively, p=0.05). Conclusions: Our study provided a proof of concept for a newly developed technique to provide high sensitivity of mutation detection in thyroid cancer. The achieved sensitivity of detection is the highest to date using liquid biopsy in this tumor type. While we addressed only BRAF mutations in our study, the same approach can potentially be used for other mutations as well, likely changing the paradigm for use of liquid biopsy in thyroid cancer.

Langerhans cell histiocytosis and thyroid carcinoma

1998 ◽  
Vol 138 (5) ◽  
pp. 909-910 ◽  
Author(s):  
Marzano ◽  
Gasparini ◽  
Grammatica ◽  
De Juli ◽  
Caputo
Keyword(s):  
Thyroid Carcinoma ◽  
Langerhans Cell Histiocytosis ◽  
Langerhans Cell

The Place of Ionizing Radiation in the Treatment of Thyroid Carcinoma

1980 ◽  
Vol 13 (1) ◽  
pp. 109-113 ◽  
Author(s):  
Lowell Millburn ◽  
Dean Ameen
Keyword(s):  
Ionizing Radiation ◽  
Thyroid Carcinoma
Sign in / Sign up

Export Citation Format

Share Document